As directors push for technology transformation, a new survey reveals a striking confidence gap in risk oversight—especially ...

The 23andMe Research Institute bought the company's assets for $305 million, scotching a proposed sale to Regeneron ...

When Carmen Thomas was growing up in Boston, her mom told her that her absent dad’s name was Joe Brown. So when she sent a saliva sample to 23andMe in her 20s and got a match with a Brown, she was ...

Regeneron Pharmaceuticals is a leading biotech focused on gene editing. While the S&P 500 has dipped lower in November, Regeneron stock has climbed steadily higher. Despite its recent rise, Regeneron ...

Tarrytown-based Regeneron Pharmaceuticals is planning to spend $2 billion to expand and upgrade its presence in Saratoga Springs in Upstate New York. The expansion is expected to create an estimated 1 ...

FDA approved EYLEA HD for macular edema post-RVO with up to 8-week dosing after initial monthly doses. Phase 3 QUASAR trial showed non-inferior visual acuity gains with EYLEA HD compared to EYLEA.

After months of back-and-and forth with the FDA and a third-party manufacturer, Regeneron has secured two long-awaited approvals for Eylea HD, gaining a new indication and a more flexible dosing ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...

The approvals come as a pleasant surprise for Regeneron, analysts say, helping bolster the overall product profile of high-dose Eylea despite outstanding manufacturing concerns. Regeneron’s high-dose ...

Every upgrade to Eylea HD’s label helps as Regeneron fights for prescriptions in an eye disease market it once dominated with original Eylea. The approval for retinal vein occlusion may open up as ...

Regeneron Pharmaceuticals received approval from the U.S. Food and Drug Administration for its eye treatment Eylea HD. The approval is for Eylea to treat macular edema following retinal vein occlusion ...